Recent advances in synthesis of PAR ligands as therapeutic strategy for inflammatory diseases

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 6, 2009, Pages 653-663

  Severino, B ^a   Santagada, V ^a   Perissutti, E ^a   Fiorino, F ^a   Frecentese, F ^a   De Angelis, F ^a   Esposito, A ^a   Caliendo, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Agonist; Antagonist; Inflammation; Peptide mimetic; Protease activated receptors; Small molecule

Indexed keywords

2 BENZOTHIENYLLEUCYLISOLEUCYLGLYCYLARGINYLLEUCYLISOLEUCINE AMIDE; 2 FUROYL LEUCYLISOLEUCYLGLYCYLARGINYLLEUCINE AMIDE; 2 INDOLYLLEUCYLISOLEUCYLGLYCYLARGINYLLEUCYLISOLEUCINE AMIDE; 2 NAPHTYLLEUCYLISOLEUCYLGLYCYLARGINYLLEUCYLISOLEUCINE AMIDE; 3 BENZOFURANYLLEUCYLISOLEUCYLGLYCYLARGINYLLEUCYLISOLEUCINE AMIDE; AC 264613; AC 55541; AC 98170; ANTIINFLAMMATORY AGENT; ENMD 1068; HIMBACINE; P4PAL10; PEPDUCIN; PEPTIDOMIMETIC AGENT; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 4; RWJ 54003; RWJ 56110; RWJ 58259; SCH 530348; SCH 79797; SERYLLEUCYLISOLEUCYLGLYCYLARGININE 3 BENZOTHIENYLALANYLISOLEUCINE AMIDE; SERYLLEUCYLISOLEUCYLGLYCYLARGININE 3,4 DICHLOROPHENYLALANYLISOLEUCINE AMIDE; SERYLLEUCYLISOLEUCYLGLYCYLARGININE 4 NITROPHENYLALANYLISOLEUCINE AMIDE; SERYLLEUCYLISOLEUCYLGLYCYLARGINYLLEUCYLISOLEUCINE AMIDE; SERYLLEUCYLISOLEUCYLGLYCYLARGINYLTYROSYLISOLEUCINE AMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YD 3; BIOMIMETIC MATERIAL; HETEROCYCLIC COMPOUND; LIGAND; ORGANIC COMPOUND;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; INFLAMMATORY DISEASE; LIVER CIRRHOSIS; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TARGETING; SHORT SURVEY; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG POTENTIATION; INFLAMMATION; METABOLISM; REVIEW; SYNTHESIS;

ANIMALS; BIOMIMETIC MATERIALS; HETEROCYCLIC COMPOUNDS; HUMANS; INFLAMMATION; LIGANDS; ORGANIC CHEMICALS; RECEPTORS, PROTEINASE-ACTIVATED;

EID: 69249202423     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788452711     Document Type: Short Survey

References (72)

1. Vu, T.K.H.; Hung, D.T.; Wheaton, V.I.; Coughlin, S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell, 1991, 64, 1057-68.
2. 2+ mobilization. FEBS Lett., 1991, 288, 123-8.
3. Nystedt, S.; Emilsson, K.; Wahlestedt, C.; Sundelin, J. Molecular cloning of a potential proteinase activated receptor. Proc. Natl. Acad. Sci. USA, 1994, 91, 9208-12.
4. Hollenberg, M.D. Protease-mediated signalling: new paradigms for cell regulation and drug development. Trends Pharmacol. Sci., 1996, 17, 3-6.
5. Ishihara, H.; Connolly, A.J.; Zeng, D.; Kahn, M.L.; Zheng, Y.W.; Timmons, C.; Tram, T.; Coughlin, S.R. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature (London), 1997, 356, 502-6.
6. Dery, O.; Corvera, U.; Steinhoff, M.; Bunnett, N.W. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am. J. Physiol., 1998, 274, C1429-52.
7. Hollenberg, M.D. Protease-activated receptors: PAR4 and counting: how long is the course? Trends Pharmacol. Sci., 1999, 20, 271-3.
8. Coughlin, S.R. Thrombin signaling and protease-activated receptors. Nature, 2000, 407, 258-64.
9. Cocks, T.M.; Moffatt, J.D. Protease activated receptors: sentries for inflammation? Trends Pharmacol. Sci., 2000, 21, 103-8.
10. Macfarlane, S.R.; Seatter, M.J.; Kanke, T.; Hunter, G.D.; Plevin, R. Proteinase-Activated Receptors. Pharmacol. Rev., 2001, 53(2), 245-82.
11. Hollenberg, M.D.; Compton S.J. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol. Rev., 2002, 54, 203-17.
12. Coughlin, S.R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost., 2005, 3, 1800-14.
13. Steinhoff, M.; Buddenkotte, J.; Shpacovitch, V.; Rattenholl, A.; Moormann, C.; Vergnolle, N. Proteinase-Activated Receptors: Transducers of Proteinase-Mediated Signaling in Inflammation and Immune Response. Endocr. Rev., 2005, 26, 1-43.
14. Vergnolle, N.; Cellars, L.; Mencarelli, A.; Rizzo, G.; Swaminathan, S.; Beck, P.; Steinhoff, M.; Andrade-Gordon, P.; Bunnett, N.W.; Hollenberg, M.D.; Wallace, J.L.; Cirino, G.; Fiorucci, S. A role for proteinase-activated receptor - 1 in inflammatory bowel diseases. J. Clin. Invest., 2004, 114(10), 1444-56.
15. Vergnolle, N.; Wallace, J.L.; Bunnett, N.W.; Hollenberg, M.D. Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol. Sci., 2001, 22, 146-52.
16. Lourbakos, A.; Potempa, J.; Travis, J.; D'Andrea, M.R.; Andrade-Gordon, P.; Santulli, R.; Mackie, E.J.;Pike, R.N. Arginine-Specific Protease from Porphyromonas gingivalis Activates Protease-Activated Receptors on Human Oral Epithelial Cells and Induces Interleukin-6 Secretion. Infect. Immun., 2001, 69, 5121-30.
17. Scarborough, R.M.; Naughton, M.A.; Teng, W.; Hung, D.T.; Rose, J.; Vu, T.K. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J. Biol. Chem., 1992, 267, 13146-49.
18. Chackalamannil, S. Thrombin Receptor (Protease Activated Receptor-1) Antagonists as Potent Antithrombotic Agents with Strong Antiplatelet Effects. J. Med. Chem., 2006, 49, 5389-403.
19. Martorell, L.; Martinez-Gonzalez, J.; Rodriguez, C.; Gentile, M.; Calvayrac, O.; Badimon, L. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb. Haemost., 2008, 99(2), 305-15.
20. Leger, A.J.; Covic, L.; Kuliopulos, A. Protease-activated receptors in cardiovascular Diseases. Circulation, 2006, 114(10), 1070-77.
21. Napoli, C.; Cicala, C.; Wallace, J.L.; De Nigris, F.; Santagada, V.; Caliendo, G.; Franconi, F.; Ignarro, L.J.; Cirino, G. Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart. Proc. Natl. Acad. Sci. USA, 2000, 97(7), 3678-83.
22. Cicala, C.; Morello, S.; Santagada, V.; Caliendo, G.; Sorrentino, L.; Cirino, G. Pharmacological dissection of vascular effects caused by activation of protease-activated receptors 1 and 2 in anesthetized rats. FASEB J., 2001, 15(8), 1433-35.
23. Napoli, C.; De Nigris, F.; Cicala, C.; Wallace, J.L.; Caliendo, G.; Condorelli, M.; Santagada, V.; Cirino, G. Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning. Am. J. Physol., 2002, 282, H2004-10.
24. Boven, L.A. Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis. J. Immunol., 2003, 170, 2638-46.
25. Copple, B.L.; Moulin, F.; Hanumegowda, U.M.; Ganey, P.E.; Roth, R.A. Thrombin and protease-activated receptor-1 agonists promote lipopolysaccharide-induced hepatocellular injury in perfused livers. J. Pharmacol. Exp. Ther., 2003, 305, 417-25.
26. Vergnolle, N.; Hollenberg, M.D.; Wallace, J.L. Pro- and anti-inflammatory actions of thrombin: a distinct role for proteinase-activated receptor-1 (PAR-1). Br. J. Pharmacol., 1999, 126, 1262-68.
27. Coughlin, S.R.; Camerer, E. PARticipation in inflammation. J. Clin. Invest., 2003, 111, 25-7.
28. Asokananthan, N.; Graham, PT; Fink, J; Knight, DA; Bakker, AJ; McWilliam, AS; Thompson, PJ; Stewart, GA. Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J. Immunol., 2002, 168, 3577-85.
29. Sokolova, E.; Reiser, G. A novel therapeutic target in various lung diseases: Airway proteases and protease-activated receptors. Pharmacol. Ther., 2007, 115, 70-83.
30. Fiorucci S.; Mencarelli A.; Palazzetti B.; Distrutti E.; Vergnolle N.; Hollenberg, M.D.; Fallace, J.L.; Morelli, A.; Cirino, G. Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis. Proc. Natl. Acad. Sci. U S A, 2001, 98, 13936-41.
31. Hansen, K.K.; Sherman, P.M.; Cellars, L.; Andrade-Gordon, P.; Pan, Z.; Baruch, A.; Wallace, J.L.; Hollenberg, M.D.; Vergnolle, N. A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. Proc. Natl. Acad. Sci. U S A, 2005, 102, 8363-8.
32. Cenac, N.; Andrews, C.N.; Holzhausen, M.; Chapman, K.; Cottrell, G.; Andrade-Gordon, P.; Steinhoff, M.; Barbara, G.; Beck, P.; Bunnett, N.W.; Sharkey, K.A.; Ferraz, J.G.; Shaffer, E.; Vergnolle, N. Role for protease activity in visceral pain in irritable bowel syndrome. J. Clin. Invest., 2007, 17, 636-47.
33. Hyun, E.; Andrade-Gordon, P.; Steinhoff, M.; Vergnolle, N. Protease-activated receptor-2 activation: a major actor in intestinal inflammation. Gut, 2008, 57(9), 1222-9.
34. Morello, S.; Vellecco, V.; Roviezzo, F.; Maffia, P.; Cuzzocrea, S.; Cirino, G.; Cicala, C.; A protective role for proteinase activated receptor 2 in airways of lipopolysaccharide-treated rats. Biochem. Pharmacol., 2005, 71, 223-30.
35. Kelso, E.B.; Lockhart, J.C.; Hembrough, T.; Dunning, L.; Plevin, R.; Hollenberg, M.D.; Sommerhoff, C.P.; McLean, J.S.; Ferrell, W.R. Therapeutic Promise of Proteinase-Activated Receptor-2 Antagonism in Joint Inflammation. J. Pharmacol. Exp. Ther., 2006, 316, 1017-24.
36. Kawabata, A.; Matsunami, M.; Tsutsumi, M.; Ishiki, T.; Fukushima, O.; Sekiguchi, F.; Kawao, N.; Minami, T.; Kanke, T.; Saito, N. Suppression of pancreatitis-related allodynia/hyperalgesia by proteinase-activated receptor-2 in mice. Br. J. Pharmacol., 2006, 48, 54-60.
37. D'Agostino, B.; Roviezzo, F.; De Palma, R.; Terracciano, S.; De Nardo, M.; Gallelli, L.; Abbate, G.F.; D'Aiuto, E.; Russo, M.; Cirino, G.; Rossi F. Activation of protease-activated receptor-2 reduces airways inflammation in experimental allergic asthma. Clin. Exp. Allergy, 2007, 37, 1436-43.
38. 2+ signaling in mouse lung alveolar epithelial cells. Life Sci., 2007, 81, 794-802.
39. Jesmin, S.; Gando, S.; Matsuda, N.; Sakuma, I.; Kobayashi, S.; Sakuraya, F.; Hattori, Y. Temporal changes in pulmonary expression of key procoagulant molecules in rabbits with endotoxin-induced acute lung injury: elevated expression levels of protease-activated receptors. Thromb. Haemost., 2004, 92, 966-79.
40. Slofstra, S.H.; Bijlsma, M. F.; Groot, A. P.; Reitsma, P.H.; Lindhout, T.; ten Cate, H.; Spek, C.A. Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. Blood, 2007, 110(9), 3176-82.
41. Maryanoff, B.E. Adventures in drug discovery: potent agents based on ligands for cell-surface receptors. Acc. Chem. Res., 2006, 39, 831-40.
42. Andrade-Gordon, P.; Maryanoff, B.E.; Derian, C.K.; Zhang, H.C.; Addo, M.F.; Darrow, A.L.; Eckardt, A.J.; Hoekstra, W.J.; McComsey, D.F.; Oksenberg, D.; Reynolds, E.E.; Santulli, R.J.; Scarborough, R.M.; Smith, C.E.; White, K.B. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc. Natl. Acad. Sci. USA, 1999, 96, 12257-62.
43. Zhang, H.C.; Derian, C.K.; Andrade-Gordon, P.; Hoekstra, W.J.; McComsey, D.F.; White, K.B.; Poulter, B.L.; Addo, M.F.; Cheung, W.M.; Damiano, B.P.; Oksenberg, D.; Reynolds, E.E.; Pandey, A.; Scarborough, R.M.; Maryanoff, B.E. Discovery and optimization of a novel series of thrombin receptor (PAR-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates. J. Med. Chem., 2001, 44, 1021-24.
44. Zhang, H.C.; McComsey, D.F.; White, K.B.; Addo, M.F.; Andrade-Gordon, P.; Derian, C.K.; Oksenberg, D.; Maryanoff, B.E. Thrombin receptor (PAR-1) antagonists. Solid-Phase synthesis of indole-Based peptide mimetics by anchoring to a secondary amide. Bioorg. Med. Chem. Lett., 2001, 11, 2105-9.
45. Fiorucci, S.; Antonelli, E.; Distrutti, E.; Severino, B.; Fiorentina, R.; Baldoni, M.; Caliendo, G.; Santagada, V.; Morelli, A.; Cirino G. PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology, 2004, 39, 365-75.
46. Severino, B.; Fiorino, F.; Perissutti, E.; Frecentese, F.; Cirino, G.; Roviezzo, F.; Santagada, V.; Caliendo, G. Synthesis and pharmacological evaluation of peptide-mimetic protease-activated receptor-1 antagonists containing novel heterocyclic scaffolds. Bioorg. Med. Chem., 2008, 16, 6009-20.
47. Chackalamannil, S.; Xia, Y.; Greenlee,W. J.; Clasby, M.; Doller, D.; Tsai, H.; Asberom, T.; Czarniecki, M.; Ahn, H.S.; Boykow, G.; Foster, C.; Agans-Fantuzzi, J.; Bryant, M.; Lau, J.; Chintala, M. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J. Med. Chem., 2005, 48, 5884-87.
48. Chackalamannil, S.; Davies, R.J.; Asberom, T.; Doller, D.; Leone, D. A Highly efficient total synthesis of (+)-himbacine. J. Am. Chem. Soc., 1996, 118, 9812-3.
49. Xia, Y.; Chackalamannil, S.; Chan, T.M.; Czarniecki, M.; Doller, D.; Eagen, K.; Greenlee, W.J.; Tsai, H.; Wang, Y.; Ahn, H.S.; Boykow, G.C.; McPhail, A.T. Himbacine derived thrombin receptor (PAR-1) antagonists: structure-activity relationship of the lactone ring. Bioorg. Med. Chem Lett., 2006, 16(18), 4969-72.
50. Chackalamannil, S.; Wang, Y.; Greenlee, W.J.; Hu, Z.; Xia, Y.; Ahn, H.S.; Boykow, G.; Hsieh, Y.; Palamanda, J.; Agans-Fantuzzi, J.; Kurowski, S.; Graziano, M.; Chintala, M. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J. Med. Chem., 2008, 51, 3061-4.
51. Ahn, H.; Arik, L.; Boykow, G.; Burnett, D.A.; Caplen, M.A.; Czarniecki, M.; Domalski, M. S.; Foster, C.; Manna, M.; Stamford, A. W.; Wu, Y. Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists. Bioorg. Med. Chem. Lett., 1999, 9, 2073-8.
52. Strande, J.L.; Hsu, A.; Su, J.; Fu, X.; Gross, G. J.; Baker, J. E. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/ reperfusion injury in rat hearts. Basic Res. Cardiol., 2007, 102, 350-8.
53. Zania, P.; Kritikou, S.; Flordellis, C.S.; Maragoudakis, M.E.; Tsopanoglou, N.E. Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis. J. Pharmacol. Exp. Ther., 2006, 318, 246-54.
54. Di Serio, C.; Pellerito, S.; Duarte, M.; Massi, D.; Naldini, A.; Cirino, G.; Prudovsky, I.; Cantucci, M.; Geppetti, P.; Marchionni, N.; Casotti, G.; Tarantini, F. Protease-activated receptor 1-selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism. Basic Clin. Pharmacol. Toxicol., 2007, 101, 63-9.
55. Maryanoff, B.E.; Santulli, R.J.; McComsey, D.F.; Hoekstra, W.J.; Hoey, K; Smith, C.E.; Addo, M.; Darrow, A.L.; Andrade-Gordon P. Protease-activated receptor-2 (PAR-2): structure-function study of receptor activation by diverse peptides related to tethered-ligand epitopes. Arch. Biochem. Biophys., 2001, 386, 195-204.
56. Santagada, V.; Caliendo, G.; Severino, B.; Perissutti, E.; Fiorino, F.; Cicala, C.; De Filippis, V.; Cirino, G. Minimal Structural Requirements for Agonist Activity of PAR-2 Activating Peptides. Bioorg. Med. Chem. Lett., 2002, 12(1), 21-4.
57. Kanke, T.; Ishiwata, H.; Kabeya, M.; Saka, M.; Doi, T.; Hattori, Y.; Kawabata, A.; Plevin, R. 2-Furoyl-LIGRL-NH2, a potent agonist for proteinase-activated receptor-2, as a gastric mucosal cytoprotective agent in mice. Br. J. Pharmacol., 2005, 144(2), 212-9.
58. Barry, G.D.; Suen, J.Y.; Low, H.B.; Pfeiffer, B.; Flanagan, B.; Salili, M.; Le G.T.; Fairlie, D.P. A refined agonist pharmacophore for protease activated receptor 2. Bioorg. Med. Chem. Lett., 2007, 17, 5552-7.
59. Devlin, M.G.; Pfeiffer, B.; Flanagan, B.; Beyer, R. L.; Cocks, T.M.; Fairlie D.P. Hepta and octapeptide agonists of protease-activated receptor 2. J. Pept. Sci., 2007, 13, 856-61.
60. Ramachandran, R.; Hollenberg, M.D. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br. J. Pharmacol., 2008, 53, S263-82.
61. Kawabata, A.; Kanke, T.; Yonezawa, D.; Ishiki, T.; Saka, M.; Kabeya, M.; Sekiguchi, F.; Kubo, S.; Kuroda, R.; Iwaki, M.; Katsura, K.; Plein, R. Potent and Metabolically Stable Agonists for Protease-Activated Receptor-2: Evaluation of Activity in Multiple Assay Systems in Vitro and in Vivo. J. Pharmacol. Exp. Ther., 2004, 309, 1098-107.
62. Seitzberg, J.G.; Knapp, A.E.; Winther Lund, B.; Mandrup Bertozzi, S.; Currier, E.A.; Ma, J.; Sherbukhin, V.; Burstein, E.S.; Olsson, R. Discovery of potent and selective small-molecule PAR-2 agonists J. Med. Chem., 2008, 51, 5490-3.
63. Gardell, L. R.; Ma, J. N.; Seitzberg, J. G.; Knapp, A. E.; Schiffer, H. H.; Tabatabaei, A.; Davis, C.; Wong, K. K.; Lund, B. W.; Nash, N. R.; Gao, Y.; Lameh, J.; Schmelzer, K.; Olsson, R.; Burstein, E. S. Identification and characterization of novel small-molecule protease-activated receptor 2 agonists. J. Pharmacol. Exp. Ther., 2008, 327, 799-808.
64. Hollenberg, M.D.; Saifeddine, M.; Sandhu, S.; Houle, S.; Vergnolle, N. Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo. Br. J. Pharmacol., 2004, 143, 443-54.
65. Wu, C.C.; Huang, S.W.; Hwang, T.L.; Kuo, S. C.; Lee, F. Y.; Teng, C. M. YD-3, a novel inhibitor of protease-induced platelet activation. Br. J. Pharmacol., 2000, 130, 1289-96.
66. Wu, C.C.; Hwang, T.L.; Liao, C.H.; Kuo, S.C.; Lee, F.Y.; Lee, C.Y.; Teng, C.M. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3. Thromb. Haemost., 2002, 87, 1026-33.
67. Wu, C.C.; Hwang, T.L.; Liao, C.H.; Kuo, S.C.; Lee, F.Y.; Teng, C.M. The role of PAR4 in thrombin-induced thromboxane production in human platelets. Thromb. Haemost., 2003, 90, 299-308.
68. Peng C.Y.; Pan S.L.; Guh, J.H.; Liu Y.N.; Chang, Y.L.; Kuo S.C.; Lee, F.Y.; Teng, C.M. The indazole derivative YD-3 inhibits thrombin-induced vascular smooth muscle cell proliferation and attenuates intimal thickening after balloon injury. Thromb. Haemost., 2004, 92, 1232-9.
69. Chen, H.S.; Kuo, S.C. ; Teng, C.M.; Lee, F.Y.; Wang, J.P.; Lee, Y.C.; Kuo, C.W.; Huang, C.C.; Wu, C.C.; Huang, L.J. Synthesis and antiplatelet activity of ethyl-4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives. Bioorg. Med. Chem., 2008, 16, 1262-78.
70. Covic, L.; Misra, M.; Badar, J.; Singh, C.; Kuliopulos, A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med., 2002, 8, 1161-1165.
71. Wielders, S.J.H.; Bennaghmouch, A.; Reutelingsperger, C.P.M.; Bevers, E.M.; Lindhout, T. Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists. J. Thromb. Haemost., 2007, 5, 571-6.
72. Strande, J. L.; Hsu A.; Su, J.; Fu, X.; Gross G.J.; Baker, J.E. Inhibiting protease-activated receptor 4 limits myocardial ischemia/ reperfusion injury in rat hearts by unmasking adenosine signalling. J. Pharmacol. Exp. Ther., 2008, 324 (3), 1045-54.